GB001 recombinant peptide (Zhejiang Yingkang Biopharmaceutical)

Primary objective: To evaluate the effectiveness of GB001 recombinant peptide spray in adult patients with mild recurrent aphthous ulcer. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of GB001 recombinant peptide spray in adult patients with mild recurrent aphthous ulcer; 2) To evaluate the immunogenicity and safety of GB001 recombinant peptide spray in adult patients with mild recurrent aphthous ulcer.

1) In healthy adult subjects, evaluate the safety and tolerability of single and continuous oral topical use of GB001 recombinant polypeptide spray, and provide a reference dose range for the dosing regimen of Phase II clinical trials. 2) In healthy adult subjects, evaluate the retention time of the test drug in the oral cavity after a single topical use of GB001 recombinant polypeptide spray, and the human pharmacokinetic characteristics after single and multiple administrations.